– Cinryze Now Approved in Canada for Routine Prevention of Attacks of Hereditary Angioedema (HAE)

EXTON, PA, October 22, 2012 – ViroPharma Incorporated (NASDAQ: VPHM) today announced that Health Canada has granted a Notice of Compliance (NOC) and approved a New Drug Submission (NDS) for Cinryze™ (C1 inhibitor [human]). Approval of Cinryze was granted for routine prevention of angioedema attacks in adult and adolescents with hereditary angioedema (HAE). Until now, there have been no approved plasma derived C1 inhibitor therapies for routine prevention of HAE attacks in Canada. ViroPharma’s Canadian headquarters are located in Oakville, Ontario. We anticipate Cinryze to be commercially available in Canada as early as the second quarter of 2013.

Read the full press release HERE.

 

HAE Canada supports patients with hereditary angioedema.

 

HAE Canada is a patient group formed in 2010 to work with physicians, nurses, and other healthcare related professionals to create a better life for hereditary angioedema patients living in Canada.  Further information on the Health Canada Drug can also be found at the HAE Canada blog.